Altimmune is trading 5.37% down at $2.02 on October 30, 2026, with no clear company-specific explanation identified.
- The company news page lists no October 30 release; its latest item is dated October 1.
- The additional $10 million loan-facility draw reported October 29 is prior-day context, not an established explanation.
- The move is intraday; reliable volume or trading-activity details were unavailable, and available results do not establish a market or biotech-sector cause.